Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Deals

Sandoz spinout last step in Novartis’ transformation into pure-play innovative medicines company

Move comes amid reorganization prioritizing multibillion growth drivers, the U.S. market

August 25, 2022 5:07 PM UTC

In the midst of a reorganization that is prioritizing multibillion growth drivers and the U.S. market, Novartis has decided to spin out its Sandoz generics business, marking the Swiss pharma’s final step in transforming into an innovative medicines company.

After nearly a year of exploring strategic options for the Sandoz unit, Novartis AG (NYSE:NVS; SIX:NOVN) said Thursday it would commence a 100% spinout of the generics and biosimilars unit, with an expectation the separation would be completed in 2H23...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Novartis AG